ADMA Biologics

Anchored in the science of human plasma, ADMA Biologics operates as a fully vertically integrated commercial biopharmaceutical company applying patented immunotechnology to develop, manufacture, and commercialise plasma-derived biologics for patients with serious immunological disorders. Listed on NASDAQ (ticker: ADMA) and headquartered in Boca Raton, Florida, the company controls each stage of its supply chain, from plasma collection through fill-finish manufacturing and medical affairs, a model that sets it apart from conventional pharmaceutical manufacturers dependent on external plasma suppliers.

Commercial Portfolio and Plasma Collection

ADMA's marketed products include ASCENIV, an intravenous immunoglobulin (IVIG) indicated for primary humoral immunodeficiency in adults and adolescents; BIVIGAM, a broad-spectrum IVIG therapy; and Nabi-HB, a hyperimmune globulin targeting hepatitis B. These products are manufactured at the company's FDA-licensed facility in Boca Raton. Plasma supply is secured through ADMA BioCenters, its own network of plasma collection centres operating across the United States, which feed proprietary immunotechnology fractionation processes downstream.

Contract development and manufacturing services extend the company's commercial reach, allowing third-party biopharmaceutical partners to access ADMA's specialised biologics processing infrastructure. Scientific direction is guided by a dedicated Scientific Advisory Board, and the medical affairs function supports clinician engagement, publications, and advocacy for patients living with primary immunodeficiency disease.

Further information is available at admabiologics.com.